GC
ISEE

Gratus Capital’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Gratus Capital’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$282K – 194
2020
Q3 		$282K Hold
50,000
– – 0.04% 146
2020
Q2 		$255K Buy
+50,000
New +$208K 0.04% 144

Other funds holding ISEE

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Gratus Capital's ISEE Position: Q4 2020 in Review

Gratus Capital sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q4 2020, closing a stake of 50,000 shares — an estimated $282K sold.

Gratus Capital first reported a position in ISEE in Q2 2020 and held it in 2 quarters. The position peaked at $282K in Q3 2020. 120 funds tracked by Wall St. Rank hold ISEE as of Q4 2020.

  • Gratus Capital reported no remaining IVERIC bio, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Gratus Capital sold 50,000 IVERIC bio, Inc. Common Stock shares in Q4 2020, an estimated $282K.
  • Gratus Capital first reported a position in IVERIC bio, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Gratus Capital's IVERIC bio, Inc. Common Stock position peaked at $282K in Q3 2020.
  • 120 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q4 2020.

Based on Gratus Capital's 13F filing for Q4 2020, filed 3 Feb 2021.